The Department of Defense's Prostate Cancer Research Program (PCRP) is a critical investment in innovative treatments and diagnostics for prostate cancer. Through the PCRP, eight new treatments and diagnostics for prostate cancer have been developed, saving the lives of thousands of men. This makes the PCRP one of the most impactful prostate cancer research programs in existence. 

Because prostate cancer is the most commonly diagnosed non-skin cancer for men, it is vital that Congress continue to invest in this research. As you may know, the Fiscal Year 2025 Continuing Resolution cut CDMRP programs by almost 60 percent. From what we have learned, funding for PCRP has been reduced down to $75 million, a 32% cut from FY2024.

To help make up ground from these severe cuts to research, we are requesting $130 million for the PCRP within the CDMRP for FY2026. Researchers will use this funding to develop treatments that improve outcomes for men with lethal prostate cancer and improve the quality of life for thousands of prostate cancer survivors.

With prostate cancer deaths on the rise, we need your help now more than ever to increase research that will produce tools for earlier detection and later-stage treatment and save lives.